205 results match your criteria: "centre de pharmacovigilance[Affiliation]"

Translation of the REMEDI[e]S (Review of potentially inappropriate MEDIcation pr[e]scribing in Seniors) explicit criteria into seminatural language for use in prescription support systems: A multidisciplinary consensus.

Therapie

October 2024

CHU de Lille, Institut de Pharmacie, 59000 Lille, France; Université de Lille, CHU de Lille, ULR 7365, Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA), 59000 Lille, France. Electronic address:

Background: By recovering data in an ordered manner and at the right time, clinical decision support systems (CDSSs) are designed to help healthcare professionals make decisions that improve patient care.

Objectives: The aim of the present study was to translate the REMEDI[e]s tool's explicit criteria, France's first reference list of potentially inappropriate drugs for the elderly, into seminatural language, in order to implement these criteria as alert rules and then enable their computer coding in a CDSS.

Methods: This work was carried out at Lille University Hospital by a team of clinical pharmacists with expertise in the use of pharmaceutical decision support systems, in collaboration with the authors of the REMEDI[e]s tool.

View Article and Find Full Text PDF

Purpose: At Lille University Hospital, a pregnancy heart team including cardiologists, obstetricians, pediatricians, anesthetists, geneticists, and pharmacologists discusses about treatment compatibility taken during breastfeeding in pregnant women (or those wishing to be pregnant) with complex cardiovascular pathologies. Beta-blockers are among the drug most often used in these patients, and data are missing or suggest a risk to the breastfed child. The aim of this study was to evaluate the proportion of women treated with beta-blockers, identified during the multidisciplinary meeting, who breastfed and to monitor adverse effects (AEs) in newborns.

View Article and Find Full Text PDF

Cost analysis study comparing the impact of treatment with aprotinin versus tranexamic acid in cardiac surgery under cardiopulmonary bypass.

Ann Pharm Fr

November 2024

CHU de Bordeaux, unité de pharmacie clinique, service pharmacie à usage intérieur, avenue de Magellan, 33604 Pessac, France; Université Bordeaux, Inserm Bordeaux Population Health Research Center team Pharmacoepidemiology, UMR 1219, université de Bordeaux, Case 11, 146, rue Léo-Saignat, 33076 Bordeaux, France; Université Bordeaux, Inserm, biologie des maladies cardiovasculaires, U1034, avenue de Magellan, 33600 Pessac, France. Electronic address:

Article Synopsis
  • Aprotinin was taken off the market in 2008 due to safety concerns but was reintroduced in France in 2018. A study was conducted to compare its effectiveness with tranexamic acid in high-risk cardiac surgery patients.
  • Economic analysis showed no significant difference in overall costs between the two treatments, but the tranexamic acid group incurred higher costs for blood products.
  • The initial higher cost of aprotinin is compensated by the greater expenses of blood products required for patients treated with tranexamic acid.
View Article and Find Full Text PDF

COVACPREG, a French prospective cohort study of women vaccinated against COVID-19 during pregnancy.

Therapie

June 2024

Service hospitalo-universitaire de pharmacotoxicologie, centre régional de pharmacovigilance, hospices civils de Lyon, 162, avenue Lacassagne, 69424 Lyon cedex 03, France. Electronic address:

The objective of this cohort study was to describe the French population of pregnant women vaccinated against coronavirus disease 2019 (COVID-19), their pregnancy outcomes and the health status of their newborns (malformation rate, neonatal diseases, etc.), and to proactively collect and analyze reported adverse reactions over time. We conducted a prospective study using an online questionnaire.

View Article and Find Full Text PDF

Introduction: Bariatric surgery is the only treatment for severe obesity (BMI>35kg/m) currently recognized as effective both in achieving tangible and lasting weight loss, and in improving obesity-related comorbidities such as type 2 diabetes, hypertension, and cardiovascular complications. Bariatric surgery, like any other surgery of the digestive tract, can have an impact on nutrient absorption, as well as on drug absorption. The literature on drug management in bariatric surgery patients concerned mainly of case reports and retrospective studies involving a small number of patients.

View Article and Find Full Text PDF

[Funding of psychiatry in France, the problem of expensive drugs. Example of Esketamine in the case of resistant depressive episodes].

Encephale

August 2024

Service de pharmacie, hôpital Paule-de-Viguier, CHU de Toulouse, 330, avenue de Grande Bretagne, 31300 Toulouse, France; Center for Epidemiology and Research in Population Health (CERPOP), UMR 1295 Inserm, université Toulouse III, Toulouse, France.

Article Synopsis
  • In France, mental health institutions' funding is allocated annually, and Esketamine is used for treating resistant major depressive disorder since its approval in 2019.
  • The study assessed if income from treating patients with Esketamine could cover its high purchase costs; seven patients used 714 devices costing €142,800, while the institution earned €149,054 in revenue.
  • The analysis showed that 95.8% of the income was consumed by Esketamine expenses, raising concerns about drug pricing and highlighting inadequate funding for expensive psychiatric treatments.
View Article and Find Full Text PDF

Patient's reporting of adverse drug reactions: Which added value in 2023?

Therapie

April 2024

Service de pharmacologie médicale, Centre de pharmacovigilance de Toulouse, CIC1436, CHU de Toulouse, Faculté de Médecine, 31000 Toulouse, France. Electronic address:

Several studies were focused on the qualitative and quantitative analysis of serious adverse drug reactions (ADRs) leading to hospitalisation or death. These figures do not take into account ADRs in ambulatory patients affecting their quality of life. Patient reporting has the advantages of bringing novel information about ADRs.

View Article and Find Full Text PDF

Increase in hospitalisation-associated methadone intoxication in France following first COVID-19 lockdown.

Public Health

October 2023

Service de Pharmacologie Médicale, CHU de Bordeauxx, Centre de Pharmacovigilance de Bordeaux, F-33000 Bordeaux, France; University Bordeaux, INSERM, BPH, U1219, CHU de Bordeaux, F-33000 Bordeaux, France; Service de Pharmacologie Médicale, Centre d'Addictovigilance, CHU de Bordeaux, F-33000 Bordeaux, France. Electronic address:

Objectives: At the beginning of the COVID-19 pandemic, the French Addictovigilance Network drew attention to the need to facilitate access to methadone while ensuring its safe use, in order to avoid the occurrence of overdoses and deaths. The objectives of the study were to assess the impact of the lockdowns on the incidence of methadone-use-related hospitalisations (MUHs) and describe the characteristics of patients and hospitalisations.

Study Design: An interrupted time series using the unobserved components model was performed to predict the monthly incidence of MUHs in 2020 on the basis of previous years' data and compared with MUHs observed.

View Article and Find Full Text PDF

UMSARS Versus Laryngoscopy-Based Assessment of Dysphagia.

Mov Disord Clin Pract

June 2023

Clinical Investigation Center CIC1436, Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre and NeuroToul Center of Excellence in Neurodegeneration (COEN) of Toulouse INSERM, University of Toulouse 3, CHU of Toulouse Toulouse France.

Background: Multiple System Atrophy (MSA) dysphagia is routinely assessed by the Unified Multiple System Atrophy Rating Scale (UMSARS) part I-item 2.

Objective: To compare the UMSARS part I-item 2 with an ear/nose/throat (ENT) expert physician assessment.

Methods: We retrospectively analyzed the data of MSA patients who underwent an ENT assessment (nasofibroscopic and radioscopic exam) and an annual UMSARS assessment.

View Article and Find Full Text PDF

Patterns, predictors, and outcomes of frailty trajectories in community-dwelling older adults: Results from the FREEDOM Cohort Study.

Arch Gerontol Geriatr

November 2023

Laboratoire VieSanté - UR 24134 (Vieillissement, Fragilité, Prévention, e-Santé), Institut Omega Health, Université de Limoges, Limoges, France; CHU de Limoges, Pôle HU Gérontologie Clinique, F-87042 Limoges, 2 Avenue Martin-Luther King, France; Unité de Recherche Clinique et d'Innovation (URCI) de Gérontologie, CHU de Limoges, Pôle HU Gérontologie Clinique, Limoges, France.

Objectives: To identify subgroups of people with distinct frailty trajectories, identify baseline characteristics associated with these trajectories, and determine their coincident clinical outcomes.

Design: This study examined the longitudinal database from the FREEDOM Cohort Study.

Setting And Participants: All 497 participants of the FREEDOM (French Acronym for "FRagilitéEtEvaluation àDOMicile" / In English "Frailty and Evaluation at Home") cohort requested a comprehensive geriatric assessment.

View Article and Find Full Text PDF

Context: As is the case throughout France, vaccination coverage against human papillomavirus (HPV) infections in the Nouvelle-Aquitaine region is too low to limit viral circulation and to have an impact on the incidence of virus-induced pathologies.

Intervention Methodology: The Nouvelle-Aquitaine Regional Health Agency (ARS) has decided to set up a large-scale vaccination action in the 7th-grade classes of all 643 Nouvelle-Aquitaine middle schools during the 2023-2024 school year. This public health intervention targeting 11-to-13-year-olds shall bring together national education, health Insurance, the regional center for pharmaco-vigilance, and private health professionals.

View Article and Find Full Text PDF

Introduction: Two severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines, tozinameran/BNT162b2 (Comirnaty®, Pfizer-BioNTech) and elasomeran/mRNA-1273 (Spikevax®, Moderna), were approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) at the end of 2020, less than a year after the start of the coronavirus disease 2019 (COVID-19) pandemic. In France, the health authorities have requested an intensive vaccination campaign, accompanied by a reinforced and active pharmacovigilance surveillance. This surveillance and analysis of real-life data, based on spontaneous reports received by the French Network of Regional PharmacoVigilance Centers (RFCRPV), has enabled to identify numerous pharmacovigilance signals.

View Article and Find Full Text PDF

Overview of literature monitoring practice of clinical trials vigilance units in French institutional sponsors - A study from the REVISE working group.

Therapie

November 2023

Service de pharmacologie clinique, unité de vigilance des essais cliniques, CIC Inserm 1414, CHU de Rennes, 35033 Rennes, France.

Introduction: The evaluation of clinical trial (CT) safety is the main task of CT vigilance units. In addition to the management of adverse events, the units must review the literature to identify information that may impact the benefit-risk assessment of studies. In this survey, we investigated the literature monitoring (LM) activity of French Institutional Vigilance Units (IVU) from the working group "REflexion sur la VIgilance et la SEcurite des essais cliniques" (REVISE).

View Article and Find Full Text PDF

Aim: Drug shortages are a growing global health issue. The aim of the study was to evaluate the consequences of drug shortages on patient safety based on data recorded in the French National Pharmacovigilance Database.

Methods: All cases involving drug shortages reported from 1985 to the end of 2019 were extracted from the database.

View Article and Find Full Text PDF

Risk factors of frailty and functional disability in community-dwelling older adults: a cross-sectional analysis of the FREEDOM-LNA cohort study.

BMC Geriatr

September 2022

Laboratoire VieSanté - UR 24134 (Vieillissement, Fragilité, Prévention, e-Santé), Institut OMEGA HEALTH, Université de Limoges, 87000, Limoges, France.

Background: Frailty is a geriatric syndrome associated with disability and negative health outcome. To determine the factors associated with frailty and functional disability in older participants living in community in France. We included 753 community-dwelling old participants with available frailty data at baseline.

View Article and Find Full Text PDF

[Hospitalizations after substance use during the COVID-19 pandemic].

Therapie

May 2023

Service de pharmacologie médicale, CHU de Bordeaux, centre de pharmacovigilance de Bordeaux, 33000 Bordeaux, France; Université de Bordeaux, Inserm, BPH, U1219, 33000 Bordeaux, France.

View Article and Find Full Text PDF

Pulmonary toxicity of mTOR inhibitors. Comparisons of two populations: Solid organ recipients and cancer patients.

Therapie

June 2023

Service de pneumologie, centre de compétence maladies pulmonaires rares, hôpital européen Georges-Pompidou, AP-HP, 75000 Paris, France; Université de Paris, 75000 Paris, France.

Introduction: Mammalian target of rapamycin (mTOR) inhibitors-associated pneumonitis (mTOR-IP) has long been described in solid organ recipients (T) patients but more recently in cancer (K) patients. Its overall characteristics have never been compared between these 2 populations. The aim of this study was to compare them in terms of presentation, severity and outcome in T and in K patients.

View Article and Find Full Text PDF

Purpose: To develop and validate a case-finding algorithm for the identification of Non-Small Cell Lung Cancer (NSCLC) cases in a region-wide Italian pathology registry (PR).

Materials And Methods: Data collected between 2009 and 2017 in the PR and the Pharmacy Database of the University Hospital of Siena and the PR of Tuscany region were used. A NSCLC-identification algorithm based on free-text keywords and SNOMED morphology and topography codes was designed and tested on data from Siena: indication for drug use (i.

View Article and Find Full Text PDF

Pharmacovigilance and drug safety: Fair prescribing and clinical research.

Therapie

June 2022

Service de pharmacologie médicale et clinique, centre de pharmacovigilance, pharmacoépidémiologie et d'informations sur le medicament, faculté de médecine, centre hospitalier universitaire, 37, allées Jules-Guesde, 31000 Toulouse, France. Electronic address:

View Article and Find Full Text PDF

Introduction: Adverse drug reaction reports are usually manually assessed by pharmacovigilance experts to detect safety signals associated with drugs. With the recent extension of reporting to patients and the emergence of mass media-related sanitary crises, adverse drug reaction reports currently frequently overwhelm pharmacovigilance networks. Artificial intelligence could help support the work of pharmacovigilance experts during such crises, by automatically coding reports, allowing them to prioritise or accelerate their manual assessment.

View Article and Find Full Text PDF